Browse
Submit Data
Databases
API
Help

Dataset Information

36 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Decrease in pediatric inpatients with respiratory syncytial virus infection during severe acute respiratory syndrome coronavirus 2 pandemic.

ABSTRACT:

SUBMITTER: Kang Y

PROVIDER: S-EPMC8661606 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Similar Datasets

Lethal Pediatric Cerebral Vasculitis Triggered by Severe Acute Respiratory Syndrome Coronavirus 2.

Project description:BackgroundWe report the clinical, radiological, laboratory, and neuropathological findings in support of the first diagnosis of lethal, small-vessel cerebral vasculitis triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a pediatric patient.Patient descriptionA previously healthy, eight-year-old Hispanic girl presented with subacute left-sided weakness two weeks after a mild febrile illness. SARS-CoV-2 nasopharyngeal swab was positive. Magnetic resonance imaging revealed an enhancing right frontal lobe lesion with significant vasogenic edema. Two brain biopsies of the lesion showed perivascular and intraluminal lymphohistiocytic inflammatory infiltrate consistent with vasculitis. Despite extensive treatment with immunomodulatory therapies targeting primary angiitis of the central nervous system, she experienced neurological decline and died 93 days after presentation. SARS-CoV-2 testing revealed positive serum IgG and positive cerebrospinal fluid IgM. Comprehensive infectious, rheumatologic, hematologic/oncologic, and genetic evaluation did not identify an alternative etiology. Postmortem brain autopsy remained consistent with vasculitis.ConclusionThis is the first pediatric presentation to suggest that SARS-CoV-2 can lead to a fatal, postinfectious, inflammatory small-vessel cerebral vasculitis. Our patient uniquely included supportive cerebrospinal fluid and postmortem tissue analysis. While most children recover from the neurological complications of SARS-CoV-2, we emphasize the potential mortality in a child with no risk factors for severe disease.

| S-EPMC8585961 | biostudies-literature

Severe acute respiratory syndrome-associated coronavirus infection.

Project description:Whether severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infection can be asymptomatic is unclear. We examined the seroprevalence of SARS-CoV among 674 healthcare workers from a hospital in which a SARS outbreak had occurred. A total of 353 (52%) experienced mild self-limiting illnesses, and 321 (48%) were asymptomatic throughout the course of these observations. None of these healthcare workers had antibody to SARS CoV, indicating that subclinical or mild infection attributable to SARS-CoV in adults is rare.

| S-EPMC3035556 | biostudies-literature

Severe acute respiratory syndrome coronavirus 2

Project description:Mass molecular testing for COVID19 using NGS-based technology and a highly scalable workflow

| PRJNA679460 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:Research on the pathogenesis of SARS-CoV-2

| PRJDB10881 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:SARS-CoV-2 is localized in cardiomyocytes: an autopsy case

| PRJDB11530 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:A Clinical test of 2019-nCoV Nucleic acid detection kit and downstream software

| PRJNA1058688 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome sequencing

| PRJNA613958 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:Genomic Epidemiology of SARS-CoV-2 in Bangladesh

| PRJNA737163 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:SARS-CoV-2 genomic data and descriptive metadata from primary specimens collected in Ontario, Canada and sequenced and/or assembled by the McArthur Laboratory at McMaster University (Hamilton, Ontario, Canada) during the COVID-19 outbreak.

| PRJNA689621 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:In vitro Selection and Analysis of SARS-CoV-2 Nirmatrelvir Resistance Mutations Contributing to Clinical Virus Resistance Surveillance

| PRJNA1079806 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data